Extract of the Leaves of Hydrolea glabra Schum. &Thonn. (Hydrophyllaceae), Exerts Anxiolytic Effect on Swiss Albino Mice
doi.org/10.26538/tjnpr/v2i9.1
Keywords:
Anxiolytic activity,, Hydrolea glabra,, exploratory, behaviour,, sedative activity,, dementia.Abstract
The plant,Hydrolea glabra, is used in neurodegenerative disorders associated with dementia, where personality changes present as symptoms such as anxiety, depression and sleep changes. This notwithstanding, no pharmacological studies have been carried out on the anxiolytic and sedative properties of the plant. This research evaluated the anxiolytic effects of the extract of the plant, Hydrolea glabra, in order to validate the folkloric claims of its usefulness in the management of dementia. Methanol extract of the leaves of Hydrolea glabra was analysed for the phytochemical composition and the anxiolytic effect was evaluated, using the Elevated plus maze, Hole board and Phenobarbitoneinduced sleeping time models in mice. Phytochemical screening showed the presence of alkaloids, terpenoids, saponins, phenolics, condensed tannins, cardiac glycosides and reducing sugars. There was significant percentage increase (48%) in the time spent in the open arms, by the rats given the extracts, which was comparable to 42% of the standard Diazepam (1 mg/kg b.w) in the elevated plus maze model. The extract at 200mg/kg, also had a sedative effect by prolonging the phenobarbitone-induced sleeping time by 45% when compared to the standard, Diazepam. The anxiolytic effect observed may substantiate the medicinal relevance of the plant, by providing the pharmacological basis for the use of this plant in folkloric medicine practice.
References
Levenson RW, Sturm VE, Haase CM. Emotional and behavioral symptoms in neurodegenerative disease: a model for studying the neural bases of psychopathology. Ann Rev Clin Psychol. 2014; 28:581–606.
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002; 288:1475–1483.
Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, Tekin S, Lane R, Ferris S. Behavioral symptoms in mild cognitive
impairment. Neurol. 2004; 62:1199–1201.
Burke SL, O’Driscoll J, AmaryAlcide, Tan Li. Moderating risk of Alzheimer’s disease through the use of anxiolytic agents. Int. J Geriar. Psych. 017; 32(12):1312-1321.
Seligman MEP, Walker EF, Rosenhan DL. Abnormal psychology. New York: W.W. Norton & Company; 2001. p. 175.
Bierman EJM, Comijs HC, Jonker C, Scheltens P, Beekman AT. The effect of anxiety and depression on decline of memory function in Alzheimer’s disease. International Psychogeriatrics. 2009; 21:1142–1147.
Badrakalimuthu VR, Tarbuck AF. Anxiety: a hidden element in dementia. Advances in psychiatric treatment. 2012; 18:119–128.
Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA,Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P. Amyloid-β, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. JAMA Psych. 2015; 72(3):284-291.
Starkstein SE, Jorge R, Petracca G, et al. The construct of generalized anxiety disorder in Alzheimer disease. Am J Geriatric Psych.2007; 15:42–49.
Fajemiroye JO, da Silva DM, de Oliveira DR, Costa EA. Treatment of anxiety and depression: medicinal plants in retrospect. Fund Clin Pharmacol. 2016; 30(3):198-215.
Stahl SM. Essential psychopharmacology. (2nd ed.). New York: Cambridge University Press; 2000.
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Coughlin SLA. Review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim. Care Companion J Clin Psych. 2004; 6:159–166.
Baldessarini R.J. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE. (Eds.). Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGrawHill; 2001. 447–483p.
Ravindran LN., Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J. Clin. Psychiatry. 2010; 71: 839–854.
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for
Psychopharmacology. J Psychopharmacol.2005;19:567–596.
Duke JA. Medicinal plants and the pharmaceutical industry. In: Janick J, Simon JE. (Eds), New crops. New York: Wiley; 1993. 664–669p.
World Health Organization (WHO). WHO Traditional Medicine Strategy 2013; 54:2014–2023.
Hornik-Lurie T, Cwikel J, FeinsonMC, Lerner Y, Zilber N. Use of unconventional therapies by primary care patients –religious resources vs. complementary or alternative medicine services. Complement. Ther Med. 2013; 1:517–524.
Dias AD, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012; 2:303–336.
Gilani AH and Rahman AU. Trends in ethnopharmacology. JEthnopharmacol. 2005; 100: 43–49.
Templeman K and Robinson A. Integrative medicine models in contemporary primary health care. Complement. Ther. Med. 2011; 19:84–92.
BurkillHM. The useful plants of west tropical Africa. 1985; 2:636.
Akobundu IO and Agyakwa WA. A handbook of West African Weeds. Ibadan, Nigeria: International Institute of Tropical Agriculture; 1998. 50 p.
Harborne JB. Textbook of Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. (5th ed.) London: Chapman and Hall Ltd; 1998. 21-72p.
Sofowora A. Phytochemical Screening of Medicinal Plants and Traditional medicine in Africa. Spectrum Books Ltd, Ibadan, Nigeria. 1993
Pellow S, Chopin P, File SE, Briley J. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety of the rat. Neuroscience Methods. 1985; 14:144–146.
OzturkY, AydineS, Baser KHC, Berberoglu H. Effects of Hypericum perforatum L. and Hypericum calycinum L. extracts on the central nervous system in mice. Phytomed. 1996; 3(2):139–146.
Ghorbani A, Youssofabad NJ, Rakhshandeh H. Effect of Viola tricolor on pentobarbital-induced sleep in mice. Afr J Pharm Pharmacol. 2012; 6(35): 2600-2606.
Awad R, Arnason JT, Trudeau V, Bergeron C, Budzinski JW, Foster BC, Merali Z. Phytochemical and biological analysis of Skullcap (ScutellarialaterifloraL.): A medicinal plant with anxiolytic properties. Phytomed. 2003; 10:640–649.
Mullally M, Cayer C, Muhammad A, Walshe-Roussel B, Ahmed F, Sanchez-Vindas PE, Rojas MO, Merali Z, Cal V, Durst T, Trudeau VL, Amason JT. Anxiolytic activity and active principles of Piper amalago (Piperaceae), a medicinal plant used by the Q'eqchi' Maya to treat susto, a culturebound illness. J Ethnopharmacol. 2016; 185:147–154.
File SE. Behavioral detection of anxiolytic action. In: Elliott, J.M., Heal, D.J., Marsden, C.A. (Eds.), Experimental Approaches to Anxiety and Depression. New York: Wiley; 1992. 25-44p.
Cruz APM, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. PharmacolBiochem. Behav. 1994; 49:171–176.
Brown GR and Nemes C. The exploratory behaviour of rats in the hole-board apparatus: Is head-dipping a valid measure of neophilia? Behavioural Processes. 2008; 78(3):442-448.
Crawley JN. Exploratory behavior models of anxiety in mice. NeurosciBiobehavRev. 1985; 9:37–44.
Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol. 1998; 350:21–29.
Sayin U, PuraliN, Ozkan T, Altug T, Buyukdevrim S. Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. PharmacolBiochemBehav. 1992; 43:529-535.
Casarrubea M, Sorbera F, Santangelo A, Crescimanno G. Microstructure of rat behavioral response to anxiety in holeboard. Neurosci Lett. 2010; 481:82–87.
Bilkei-Gorzó A and Gyertyán I. Some doubts about the basic concept of hole-board test. Neurobiol 1996; 4(4):405-15.
Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002; 111(2): 231-239.
Datta S. Cellular and chemical neuroscience of mammalian sleep. Sleep Med. 2010; 11(5):431-440.
Chu QP, Wang LE, Cui XY, Fu HZ, Lin ZB, Lin SQ, Zhang YH. Extract of Ganoderma lucidum potentiates pentobarbital-induced sleep via a GABAergic mechanism. Pharmacol. Biochem. Behav. 2007; 86(4):693-698.
Hossain MM, Biva IJ, Jahangir R, Vhuiyan MM. Central nervous system depressant and analgesic activity of Aphanamixispolystachya(Wall.) parker leaf extract in mice. Afr J Pharm Pharmacol. 2009; 3:282-286
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
